EXTON, PA — ProRx Pharma has expanded its pharmaceutical operations with a new suite of ISO-certified clean rooms, robotics, and automated systems, positioning the company to meet rapidly rising demand for personalized and preventative medicine. The upgrades mark the latest phase of a broader expansion initiative that began in February, when ProRx doubled the size of its manufacturing footprint.
Company officials said the new capabilities come at a critical moment, as compounded medications used in preventative, functional, and longevity-focused therapies see sustained growth across telehealth, concierge practices, and clinic-based care. The expansion adds a hazardous drug ISO-8 processing room and a nonhazardous clean room for aseptic production, both equipped with automated machinery designed to reduce human contact, lower contamination risk, and increase production volume.
ProRx is also constructing two additional aseptic clean rooms—one for hazardous drugs and one for nonhazardous drugs—to further boost capacity. All new facilities meet ISO-7 certification standards, with core equipment certified to ISO-5 for critical sterile operations. Certifications are revalidated every six months.
“Humans are the biggest source of contaminants in sterile drug processing,” said Kurt Lunkwitz, chief operating officer at ProRx. He said the integration of robotics and automated logging systems strengthens sterility controls, aligns with regulatory expectations, and enhances quality safeguards. The investments, he noted, reflect the company’s commitment to safe, scalable production for a growing roster of healthcare partners.
The demand is fueled by an expanding market for therapies such as Sermorelin, NAD+, Vitamin B12, MIC+B12 blends, Glutathione, and Testosterone. ProRx’s expanded capabilities are designed to support this growth by combining advanced clean-room technology with Current Good Manufacturing Practices to deliver consistency and safety at scale.
Company officials said the upgrades will increase production capacity, improve efficiency through automation, enhance compliance with validated sterility and electronic documentation, and support new service lines.
“As preventative and longevity-focused care accelerates, healthcare providers need a 503B partner who can scale with them,” Lunkwitz said. He added that ProRx aims to remain a reliable national supplier capable of meeting rising clinical demand with high-quality compounded medications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.